Bli medlem
Bli medlem

Du är här

2020-10-21

NextCell Pharma AB: ProTrans stem cells approved for clinical trials in COVID-19 patients

ProTrans is developed as an immunomodulatory stem cell therapy presently evaluated in clinical trials treating patients with type-1 diabetes. However, the mechanism of immunomodulation is expected to be applicable in other autoimmune diseases and inflammatory conditions. The server stage of COVID-19 is when the immune system becomes hyperactive and attacks organs including the lungs. In this open phase 1b study, a total of three groups of, each three patients, will be treated with different doses of ProTrans.

Principle Investigator for the trial is Professor Josefin Sundh, University Hospital Örebro. The clinical trial protocol is written by Professor Dominique Farge, St. Louis Hospital in France, and Doctor Lindsay Davies, CSO NextCell Pharma. The steering committee is Professor Farge (chair), Professor Edvard Smith (NextCell Pharma) and Doctor Tomasz Oldak (PBKM). NextCell decided to subcontract PBKM (FamiCord Group) as Contracted Manufacturing Partner.

This information is the information that NextCell Pharma AB is required to disclose under the EU Market Abuse Regulation. The information was provided by the below contact person for publication on 21[st] of October 2020

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.